WO2022215017 - TREATMENTS FOR PRURIGO NODULARIS
National phase entry:
Publication Number
WO/2022/215017
Publication Date
13.10.2022
International Application No.
PCT/IB2022/053250
International Filing Date
07.04.2022
Title **
[English]
TREATMENTS FOR PRURIGO NODULARIS
[French]
TRAITEMENTS CONTRE LE PRURIGO NODULAIRE
Applicants **
GALDERMA HOLDING SA
Zählerweg 10
6300 Zug, CH
CHUGAI SEIYAKU KABUSHIKI KAISHA
5-1, Ukima 5-Chome, Kita-Ku
Tokyo, 115-8543, JP
Inventors
JULIA, Valerie
659 chemin des soullieres
06410 Biot, FR
KRISHNASWAMY, Jayendra Kumar
Chemin du Chateau-Sec 29
1009 Pully, FR
PIKETTY, Christophe
18 Bld Paul Baudin
45200 Montargis, FR
ROUSSEAU, Francois
4 rue de Baisinge
74500 Publier, FR
Priority Data
63/172,020
07.04.2021
US
63/323,409
24.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 16255 | |
| EPO | Filing, Examination | 84140 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 30110 |
Total: 131707 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein are treatments and preventions for prurigo nodularis (PN), antibodies and pharmaceutical compositions for use in the treatment or prevention of PN, and uses of an anti-IL-31RA antibody (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of PN. Also described herein are biomarkers of PN and methods of altering or improving these biomarkers via treatments with an antibody that binds to IL-31RA (e.g., nemolizumab).[French]
L'invention concerne des traitements thérapeutiques et prophylactiques contre le prurigo nodulaire (PN), des anticorps et des compositions pharmaceutiques destinés à être utilisés dans le traitement ou la prévention du PN, et des utilisations d'un anticorps anti-IL-31 RA (par exemple, némolizumab) dans la fabrication d'un médicament pour le traitement ou la prévention du PN. L'invention concerne également des biomarqueurs de PN et des méthodes de modification ou d'amélioration de ces biomarqueurs par l'intermédiaire de traitements avec un anticorps qui se lie à IL-31 RA (par exemple, némolizumab).